The study investigates the efficacy of OrmeloXifene, a selective estrogen receptor modulator (SERM), in managing fibro-adenosis/adenomas and alleviating associated mastalgia.

Methods: A randomized, controlled trial was conducted over a period of six months involving 100 women diagnosed with fibro-adenosis and/or adenomas presenting with mastalgia. Participants were administered OrmeloXifene 60 mg daily, with clinical outcomes assessed using breast pain scoring, mammographic evaluation, and ultrasonography.

Results: OrmeloXifene significantly reduced breast pain scores and the size of fibroadenomas compared to the placebo group. No significant adverse effects were observed.

Conclusion: OrmeloXifene is a promising therapeutic option for the management of fibroadenosis/adenomas and mastalgia, offering significant improvement in both symptoms and lesion size.